---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-25-000009"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:04:41.948080+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics expands leadership with CBO and SVP HR appointments

## Summary
- Taylor Boyd named Chief Business Officer; base salary $465k, target bonus 40%, 275k stock option inducement grant.
- Ashley Ivanowicz appointed SVP, Human Resources; receives 100k stock option inducement grant.
- Both options vest over 4 years with 12-month cliff; granted under Nasdaq inducement rule.
- Company advancing AVTX-009 in Phase 2 LOTUS trial for hidradenitis suppurativa; data readout expected mid-2026.
- Boyd previously led BD at Longboard, culminating in $2.6B acquisition by Lundbeck.

## SEC filing metadata
- accession: 0001534120-25-000009
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000009/0001534120-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000009/avtx-20250929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-25-000009
- JSON: https://secwatch.observer/filing/0001534120-25-000009.json
- Plain text: https://secwatch.observer/filing/0001534120-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.